Novo Nordisk is actively monitoring and taking action (including but not limited to issuing cease-and-desist letters) against those entities that are engaging in the unlawful sale of compounded semaglutide, disseminating false advertising, and infringing its trademarks. Scott Brunner, CEO of the Alliance for Pharmacy Compounding (A4PC), says that, based on reports from some compounding pharmacies, compounding pharmacies have been able to access semaglutide from legitimate FDA-registered facilities
Nausea is the most common side effect, which generally subsides as a persons body adjusts to the medication
La comunicacin entre las partes es sealada como un elemento relevante para sostener la relacin
The Phase 2 trial (Jastreboff et al., NEJM 2023) identified gastrointestinal effects as the most common adverse events
Tsuneki H, Sekizaki N, Suzuki T, Kobayashi S, Wada T, Okamoto T, et al
Epilepsia 53 , e204e207 (2012)